A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (EudraCT-No.: 2018-004329-10)

Beteiligte Wissenschaftlerin:
Dr. rer. medic. M. Eveslage

Studienleitung:
Univ.-Prof. Dr. med. Martin Bögemann

The goal of the ADAM trial is to determine if adjuvant apalutamide (APA) added to standard of care (SOC) in prostate cancer patients at high risk of developing subsequent metastatic disease results in prolonged biochemically recurrence-free survival after radical prostatectomy in comparison to standard of care alone. It is a randomized, open-label, phase II study in patients with high-risk, localized or locally advanced prostate cancer.